Bioventus (BVS) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bioventus (BVS) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 87.7% versus a gain of 52.3%. Over five years, BVS leads with a -7.0% price change compared with -90.6% for PACB. Bioventus is the larger company by market cap ($876.4 million vs $704.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | PACB |
|---|---|---|
| Share price | $12.83 | $2.27 |
| Market cap | $876.36M | $704.03M |
| 1-day change | +1.10% | -1.52% |
| YTD return | +70.56% | +22.99% |
| 1-year return | +87.72% | +52.32% |
| 5-year return | -6.96% | -90.57% |
| P/E ratio (TTM) | 16.45 | — |
| Forward P/E | 13.95 | — |
| EPS (TTM) | $0.78 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $3.44 |
| 52-week low | $6.37 | $1.07 |
| Distance from 52-week high | -19.27% | -34.16% |
| Analyst consensus | none | buy |
| Avg. price target upside | +37.18% | -4.64% |
| Average volume | 614.83K | 10.39M |
| Shares outstanding | 68.31M | 310.83M |
| Employees | 950 | 485 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed PACB by 35.4 percentage points over the past year.
- The two companies sit in different sectors: Bioventus in Health Care and Pacific Biosciences of California in Industrials.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 950 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
BVS vs PACB FAQ
Which is bigger, Bioventus or Pacific Biosciences of California?
Bioventus (BVS) is larger, with a market capitalization of $876.36M compared with $704.03M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BVS or PACB?
BVS returned +87.72% over the past 12 months, compared with +52.32% for PACB (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and Pacific Biosciences of California in the same industry?
No. Bioventus is in the Health Care sector, while Pacific Biosciences of California is in Industrials.